Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation

Cancers (Basel). 2022 Dec 4;14(23):5989. doi: 10.3390/cancers14235989.

Abstract

Epigenetic modifications, such as histone modifications and DNA methylation, are essential for ensuring the dynamic control of gene regulation in every cell type. These modifications are associated with gene activation or repression, depending on the genomic context and specific type of modification. In both cases, they are deposited and removed by epigenetic modifier proteins. In acute myeloid leukemia (AML), the function of these proteins is perturbed through genetic mutations (i.e., in the DNA methylation machinery) or translocations (i.e., MLL-rearrangements) arising during leukemogenesis. This can lead to an imbalance in the epigenomic landscape, which drives aberrant gene expression patterns. New technological advances, such as CRISPR editing, are now being used to precisely model genetic mutations and chromosomal translocations. In addition, high-precision epigenomic editing using dCas9 or CRISPR base editing are being used to investigate the function of epigenetic mechanisms in gene regulation. To interrogate these mechanisms at higher resolution, advances in single-cell techniques have begun to highlight the heterogeneity of epigenomic landscapes and how these impact on gene expression within different AML populations in individual cells. Combined, these technologies provide a new lens through which to study the role of epigenetic modifications in normal hematopoiesis and how the underlying mechanisms can be hijacked in the context of malignancies such as AML.

Keywords: AML; CRISPR; DNA methylation; epigenomic editing; hematopoiesis; histone modifications; leukemia; single-cell technology.

Publication types

  • Review

Grants and funding

A.R.-M. was supported by a Sir Henry Wellcome Postdoctoral Fellowship (222800/Z/21/Z) from the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission.